The Influence of Free Hemoglobin and Bilirubin on Heparin Monitoring by Activated Partial Thromboplastin Time and Anti-Xa Assay

被引:56
|
作者
Kostousov, Vadim [1 ,3 ]
Nguyen, Kim [3 ]
Hundalani, Shilpa G. [2 ,4 ]
Teruya, Jun [1 ,2 ,3 ]
机构
[1] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Texas Childrens Hosp, Div Transfus Med & Coagulat, Houston, TX 77030 USA
[4] Texas Childrens Hosp, Dept Pediat, Sect Neonatol, Houston, TX 77030 USA
关键词
EXTRACORPOREAL MEMBRANE-OXYGENATION; COAGULATION MANAGEMENT; CENTRIFUGAL PUMPS; HEMOLYSIS; ANTICOAGULATION; INTERFERENCE;
D O I
10.5858/arpa.2013-0572-OA
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-Elevated free hemoglobin (Hb) and bilirubinemia complicate extracorporeal membrane oxygenation and could affect unfractionated heparin (UH) therapy monitoring by anti-Xa assay and activated partial thromboplastin time (aPTT). Objectives.-To compare in vitro response of anti-Xa and aPTT assays to UH in samples with artificial hyperbilirubinemia and hyperhemoglobinemia and to estimate if this interference is also observed in vivo in pediatric extracorporeal membrane oxygenation. Design.-Measurement of aPTT and anti-Xa activity in plasma spiked with UH and increased concentration of free Hb and/or conjugated bilirubin. All samples with antiXa activity, antithrombin, free Hb, and bilirubin determination and infused dose of UH from inpatients on extracorporeal membrane oxygenation were extracted from the clinical patient database and analyzed. Results.-Each increment of free Hb by 100 mg/dL significantly shortened aPTT, whereas an increment of bilirubin by 6 mg/dL caused significant prolongation of aPTT and stepwise increase of free Hb and/or bilirubin in plasma decreased anti-Xa activity by 0.03 to 0.05 IU/mL. Extracorporeal membrane oxygenation samples with free Hb 50 mg/dL or greater had significantly lower anti-Xa activity compared with normal ones: 0.33 (0.25-0.42) versus 0.4 (0.31-0.48) IU/mL (P = .01), despite the identical UH infusion and similar antithrombin activity. Moderate increase of free Hb by 59 mg/dL was associated with absolute decrease of anti-Xa activity by 0.07 IU/mL. Conclusions.-Activated partial thromboplastin time and anti-Xa assay are affected by elevated level of free Hb and/or bilirubin in the presence of UH, and lower antiXa activity is noted in extracorporeal membrane oxygenation patients with elevated free Hb. Severe hemolysis and/or hyperbilirubinemia could compromise UH monitoring based on these assays.
引用
收藏
页码:1503 / 1506
页数:4
相关论文
共 50 条
  • [21] Comparing Activated Partial Thromboplastin Time and Heparin anti-Xa levels to monitor anticoagulant intensity of unfractionated heparin in Extracorporeal Membrane Oxygenation
    Dhillon, E.
    Laffan, M.
    Arachchillage, D. Jayakody
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 138 - 138
  • [22] Monitoring Unfractionated Heparin: A Review of Activated Partial Thromboplastin Time Versus Antifactor Xa
    Parker, Christine R.
    Kataria, Vivek
    AACN ADVANCED CRITICAL CARE, 2019, 30 (04) : 305 - 312
  • [23] Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin
    Ratano, Damian
    Alberio, Lorenzo
    Delodder, Frederik
    Faouzi, Mohamed
    Berger, Mette M.
    THROMBOSIS RESEARCH, 2019, 175 : 53 - 58
  • [24] Antifactor Xa levels compared to activated partial thromboplastin time for heparin monitoring.
    Coons, James
    Whitman-Purves, Emily
    Pae, Derek
    DiNella, Jeannine
    Miller, Taylor
    Althouse, Andrew
    Schmidhofer, Mark
    Smith, Roy
    PHARMACOTHERAPY, 2016, 36 (12): : E239 - E239
  • [25] Antifactor Xa Levels versus Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin
    Vandiver, Jeremy W.
    Vondracek, Thomas G.
    PHARMACOTHERAPY, 2012, 32 (06): : 546 - 558
  • [26] Effects of apixaban on prothrombin time, activated partial thromboplastin time and anti-Xa assays: a European survey
    Helin, Tuukka A.
    Pakkanen, Anja
    Lassila, Riitta
    Joutsi-Korhonen, Lotta
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2017, 55 (08) : E178 - E180
  • [27] Anti-Factor Xa and Activated Partial Thromboplastin Time Measurements for Heparin Monitoring in Mechanical Circulatory Support
    Adatya, Sirtaz
    Uriel, Nir
    Yarmohammadi, Hirad
    Holley, Christopher T.
    Feng, Amy
    Roy, Samit S.
    Reding, Mark T.
    John, Ranjit
    Eckman, Peter
    Zantek, Nicole D.
    JACC-HEART FAILURE, 2015, 3 (04) : 314 - 322
  • [28] Conversion From Activated Clotting Time to Anti-Xa Heparin Activity Assay for Heparin Monitoring During Extracorporeal Membrane Oxygenation*
    Villalba, Cristina A. Figueroa
    Brogan, Thomas, V
    McMullan, D. Michael
    Yalon, Larissa
    Jordan, D. Ian
    Chandler, Wayne L.
    CRITICAL CARE MEDICINE, 2020, 48 (12) : E1179 - E1184
  • [29] Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin
    Wahking, Rebekah A.
    Hargreaves, Rachel H.
    Lockwood, Sean M.
    Haskell, Sabrina K.
    Davis, Kelly W.
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (08) : 801 - 805
  • [30] Variation in coagulation factor activity levels cause discrepancies between activated partial thromboplastin time and anti-Xa activity for heparin monitoring: a retrospective observational study
    Tomoyo Saito
    Mineji Hayakawa
    Osamu Kumano
    Yoshinori Honma
    Mone Murashita
    Jun Kato
    Syouki Fukui
    Masaki Takahashi
    Yuki Takahashi
    Takumi Tsuchida
    Asumi Mizugaki
    Shuhei Takauji
    Mariko Hayamizu
    Tomonao Yoshida
    Kenichi Katabami
    Takeshi Wada
    Kunihiko Maekawa
    Journal of Intensive Care, 11